keyword
MENU ▼
Read by QxMD icon Read
search

Canagliflozin

keyword
https://www.readbyqxmd.com/read/29349558/sglt2-inhibitors-and-mechanisms-of-hypertension
#1
REVIEW
Alexandros Briasoulis, Omar Al Dhaybi, George L Bakris
PURPOSE OF REVIEW: We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension. RECENT FINDINGS: Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C. Treatment with any of the three currently FDA-approved SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) results in sustained systolic and diastolic blood pressure reduction, in part via minimal natriuresis and possible reductions in sympathetic tone...
January 19, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29341404/intra-and-inter-subject-variability-for-increases-in-serum-ketone-bodies-in-patients-with-type-2-diabetes-treated-with-the-sodium-glucose-co-transporter-2-inhibitor-canagliflozin
#2
David Polidori, Hiroaki Iijima, Maki Goda, Nobuko Maruyama, Nobuya Inagaki, Peter A Crawford
SGLT2 inhibitors have been associated with increased serum ketone bodies in patients with type 2 diabetes mellitus (T2DM). This analysis evaluated serum ketone body levels and variability in 1,278 Japanese patients with T2DM treated with canagliflozin 100 or 200 mg. Similar mean increases in ketone body concentrations of ~2-fold were seen with both canagliflozin doses. Median (interquartile range) percent change from baseline was 62% (0;180) for acetoacetate and 78% (2;236) for β-hydroxybutyrate. Approximately 2/3 of the variability in each ketone measure was attributed to intra-subject variability...
January 17, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29337457/-pharmacovigilance-update
#3
Françoise Livio
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29334278/a-comparative-safety-review-between-glp-1-receptor-agonists-and-sglt2-inhibitors-for-diabetes-treatment
#4
Agostino Consoli, Gloria Formoso, Maria Pompea Antonia Baldassarre, Fabrizio Febo
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials. Since it is therefore very likely that GLP-1RA and SGLT2i use will become more and more common, it is more and more important to gather and discuss information about their safety profile...
January 15, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29327905/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes
#5
Bruce Neal, Vlado Perkovic, David R Matthews
No abstract text is available yet for this article.
November 23, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327904/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes
#6
Sanjay Rajagopalan, Robert Brook
No abstract text is available yet for this article.
November 23, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327903/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes
#7
M Mercè Fernández-Balsells, Lidia Sojo-Vega, Wifredo Ricart-Engel
No abstract text is available yet for this article.
November 23, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327902/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes
#8
Piero Baglioni
No abstract text is available yet for this article.
November 23, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29319909/inhibitory-effects-of-sulfonylureas-and-non-steroidal-anti-inflammatory-drugs-on-in-vitro-metabolism-of-canagliflozin-in-human-liver-microsomes
#9
Sara Algeelani, Dalal Alkhelb, David J Greenblatt
Canagliflozin, used to treat type 2 diabetes mellitus (T2DM), is commonly co-administered with sulfonylureas. The objective of the present study was to evaluate the possible inhibitory effect of sulfonylureas and non-steroidal anti-inflammatory drugs (NSAIDs) on canagliflozin metabolism in vitro. Three sulfonylurea derivatives were evaluated as inhibitors: chlorpropamide, glimepiride, and gliclazide. Two other NSAIDs were used as positive control inhibitors: niflumic acid and diclofenac. The rate of formation of canagliflozin metabolites was determined by HPLC analysis of vitro incubations of canagliflozin as a substrate with and without inhibitors, using human liver microsomes (HLMs)...
January 10, 2018: Biopharmaceutics & Drug Disposition
https://www.readbyqxmd.com/read/29313267/impact-of-canagliflozin-treatment-on-health-related-quality-of-life-among-people-with-type-2-diabetes-mellitus-a-pooled-analysis-of-patient-reported-outcomes-from-randomized-controlled-trials
#10
Jennifer Cai, Linda M Delahanty, Sydney Akapame, April Slee, Shana Traina
BACKGROUND: Evidence from patient-reported outcomes in clinical trials may explain health-related behaviors observed in the real world. OBJECTIVE: The purpose of this analysis was to evaluate the effect of treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with placebo or sitagliptin on health-related quality-of-life outcomes in participants with type 2 diabetes mellitus from the clinical development program. METHODS: Patient-reported outcomes data from four randomized controlled trials of canagliflozin (n = 2536) were pooled and analyzed to evaluate participants' interest in continuing study medication; satisfaction with weight; and physical, mental, and emotional health after 26-52 weeks of treatment with canagliflozin vs...
January 8, 2018: Patient
https://www.readbyqxmd.com/read/29297732/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes
#11
Robert Guthrie
Review of: Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017: 377; 644-657. The report combines the data from two trials, CANVAS and CANVAS-Renal, which were designed to evaluate the safety and effect of canagliflozin, an SGLT-2 inhibitor, on the appearance of cardiovascular and renal events in patients with type 2 diabetes. Enrollees were patients with type 2 diabetes of at least 30 years of age, with a glycated hemoglobin of > or equal to 7...
January 3, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29285506/canagliflozin-lowers-blood-sugar-but-does-it-also-lower-cardiovascular-risk-maybe-not
#12
EDITORIAL
Thomas F Heston, Anndres H Olson, Nicholas R Randall
No abstract text is available yet for this article.
December 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29285458/sodium-glucose-cotransporter-2-inhibitors-moving-beyond-the-glycemic-treatment-goal
#13
REVIEW
Vishal Gupta, William Canovatchel, B N Lokesh, Ravi Santani, Nishant Garodia
Revelations of the multifactorial pathogenesis of type 2 diabetes mellitus (T2DM) that extend beyond the role of insulin and glucose utilization have been crucial in redefining the treatment paradigm. The focus of treatment is currently directed towards achieving wide-ranging targets encompassing the management of cardiovascular comorbidities that have been evidenced as indispensable aspects of T2DM. While most currently prescribed antihyperglycemic agents have little or no effect on reducing cardiovascular risks, some have been associated with undesirable effects on common risk factors such as weight gain and cardiovascular sequelae...
November 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29279644/canagliflozin-associated-diabetic-ketoacidosis-with-lower-than-anticipated-glucose-levels
#14
Sonali Vadi, Manjusha Agarwal
The Food and Drug Administration has approved the use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for use in Type II diabetics. These are a relatively new addition to the armamentaria of diabetes management. Postmarketing surveillance is a witness to several side effects, a morbid one being ketoacidosis. Herein is discussed a scenario of a Type II diabetic who presented with substantial ketoacidosis without significant hyperglycemia. The absence of the customary precipitating factors and the presence of a recent introduction of canagliflozin, a SGLT-2 inhibitor to the diabetes prescription, hinted at the causal relationship...
November 2017: Indian Journal of Critical Care Medicine
https://www.readbyqxmd.com/read/29278441/diabetes-news
#15
Ann M Carracher, Payal H Marathe, Kelly L Close
The American Heart Association's 2017 Scientific Sessions took place in November 2017 in Anaheim, CA, USA. Dr Kenneth Mahaffey (Stanford University, CA, USA) discussed a subgroup analysis1 of the Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial,2 suggesting consistent heart failure and renal benefits to the sodium/glucose cotransporter 2 (SGLT-2) inhibitor Invokana (canagliflozin) across primary and secondary prevention cohorts.
December 26, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/29251018/cardiovascular-outcomes-with-canagliflozin-is-it-on-the-canvas
#16
Sheila Doggrell
Sodium-glucose cotransporter 2 (SGLT2) inhibitors (the 'gliflozins') promote the excretion of glucose from the kidney to lower HbA1c. Empagliflozin was the first gliflozin shown to improve cardiovascular and renal outcomes in subjects with type 2 diabetes and cardiovascular disease. Areas covered: In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, there were improvements in the primary cardiovascular and exploratory renal outcomes with canagliflozin, compared to placebo. The safety outcome finding, which was of most interest, was that there was a higher risk of amputation of toes, feet, or legs with canagliflozin than in the placebo group...
December 18, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29238696/identification-of-clinically-approved-drugs-indacaterol-and-canagliflozin-for-repurposing-to-treat-epidermal-growth-factor-tyrosine-kinase-inhibitor-resistant-lung-cancer
#17
Hongjian Li, Christy Wing-Sum Tong, Yee Leung, Man-Hon Wong, Kenneth Kin-Wah To, Kwong-Sak Leung
In advanced lung cancer, epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) have extraordinary clinical efficacy. However, their usefulness is severely compromised by drug resistance mediated by various mechanisms, the most important of which is the secondary EGFR T790M mutation. The mutation blocks the binding of EGFR TKIs to the receptor kinase, thereby abolishing the therapeutic efficacy. In this study, we used our free and open-source protein-ligand docking software idock to screen worldwide approved small-molecule drugs against EGFR T790M...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29236983/cardioprotective-anti-hyperglycaemic-medications-a-review-of-clinical-trials
#18
Haitham M Ahmed, Haitham Khraishah, Leslie Cho
Despite extensive clinical efforts to achieve stricter glycaemic control over the past few decades, cardiovascular (CV) disease remains the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor (GLP-1-R) agonists have gained attention due to their apparent effects in reducing CV mortality. Four CV randomized controlled trials: EMPA-REG, CANVAS, LEADER, and SUSTAIN-6, found a decrease in CV events among patients with type 2 diabetes on empagliflozin, canagliflozin, liraglutide, and semaglutide, respectively...
December 9, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29236222/an-indirect-comparison-of-changes-in-the-impact-of-weight-on-quality-of-life-among-subjects-with-type-2-diabetes-treated-with-antihyperglycemic-agents-in-dual-therapy-with-metformin
#19
Shana B Traina, April Slee, Suzy Van Sanden, Joris Diels
INTRODUCTION: It is important to capture the patient experience with a diabetes treatment in clinical trials; however, use of instruments to assess patient-reported outcomes (PROs) in diabetes trials is inconsistent and results may not be reported alongside primary efficacy data. In lieu of head-to-head data, indirect comparisons can be used to compare competing interventions. In this study, we used indirect comparison methods to assess differences in PRO score changes between canagliflozin and other antihyperglycemic agents as add-on to metformin...
December 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29227973/will-canagliflozin-lend-credence-to-the-potential-effects-of-sodium-glucose-co-transporter-2-inhibitors-on-renal-endpoints-in-diabetic-nephropathy
#20
Joshua J Neumiller, Connie M Rhee, Kamyar Kalantar-Zadeh
No abstract text is available yet for this article.
December 11, 2017: American Journal of Nephrology
keyword
keyword
14923
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"